A cost-effectiveness analysis of the ZIRA test in breast cancer

Carole Siani, Lionel Perrier, Christian de Peretti(Université Claude Bernard Lyon 1), Julie A. Vendrell(Inserm), N. Plommet, Pascale A. Cohen(Lyon 1 Université), Thomas Bachelot(Centre Léon Bérard), Balázs Győrffy(Semmelweis University)

RePEc: Research Papers in Economics

May 21, 2016

Cited by 0

Related Papers

Online Survival Analysis Software to Assess the Prognostic Value of Biomarkers Using Transcriptomic Data in Non-Small-Cell Lung Cancer

|PLoS ONE|2013|1.9k

Early breast cancer: ESMO Clinical Practice Guideline for diagnosis, treatment and follow-up

|Annals of Oncology|2023|830

Intracranial Efficacy and Survival With Tucatinib Plus Trastuzumab and Capecitabine for Previously Treated HER2-Positive Breast Cancer With Brain Metastases in the HER2CLIMB Trial

|Journal of Clinical Oncology|2020|556

Comparative genomic hybridisation array and DNA sequencing to direct treatment of metastatic breast cancer: a multicentre, prospective trial (SAFIR01/UNICANCER)

|The Lancet Oncology|2014|410

Cracking the Estrogen Receptor's Posttranslational Code in Breast Tumors

|Endocrine Reviews|2011|302